Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. - Wikidata - awgldk - TriplyDB

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

http://www.wikidata.org/entity/Q36856816

about

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives The value of trabectedin in the treatment of soft tissue sarcoma Trabectedin for advanced soft tissue sarcomas: optimizing use Recent advances in targeted therapy for Ewing sarcoma Trabectedin in soft tissue sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma Nature's bounty - drug discovery from the sea Rubrolide R: a new furanone metabolite from the ascidian Synoicum of the Indian Ocean.The evolution of systemic therapy in sarcoma.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.Role of trabectedin in the treatment of soft tissue sarcoma Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study Liposarcoma in children and young adults: a multi-institutional experience.Trabectedin: safety and efficacy in the treatment of advanced sarcoma Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma.PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma Epidemiology and therapies for metastatic sarcoma Emerging therapies for adult soft tissue sarcoma.Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Advances in the targeted therapy of liposarcoma.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience.Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

P2860

Q26745502-9CA59ECB-C06C-475D-B99E-80B1CB1806DC Q26772855-25CDC045-55A8-47C4-B1F2-8C730D41E803 Q26860365-E05D3FCF-0E4E-4222-9CA5-A04ADD957D98 Q28079316-7C31E880-C4FF-4EB0-9FA8-E45439B2E5B1 Q28085505-229E5F56-FA4F-478A-B70D-16F8A2E28ED3 Q28087771-E580D9BD-1F11-4CAC-8B6F-176174F02F87 Q28307320-04DA311D-146C-49BD-8273-A6DCC4ACC45C Q28482357-685308D6-95BC-4A69-AC5E-6CB01DFC8DD9 Q28828257-021299B8-D54A-4727-90AD-695BD721752A Q30662541-9059B8FB-ABD1-49D0-868E-0E8C66FFBBA7 Q33274710-F6D43CC0-7CE3-4482-AF83-4DDECBC795AD Q33380903-D9312CB0-397D-4383-A3B2-6C76D04EA275 Q33381641-EE846F99-8B46-4852-A4CB-8F38F19B0104 Q33384836-E089232A-10F0-478B-A0E5-5724AA67BCEF Q33426789-1DFBDF28-8267-41E9-B86D-1A52E6A510DD Q33523297-95822200-75EE-469C-834A-0CB7810259BB Q33561602-C1EF448B-AA95-4F10-88FF-7C0C6EAC887C Q33648002-CF19AB56-D635-414B-A97C-7DFED79A125F Q33649056-F7652184-6BFA-4687-BCBF-596CB93BB52B Q33757142-B33C7B83-3A71-4C66-A5A9-EEE88E0877CE Q33916011-4B45341E-B987-4F5D-B727-797984DC387A Q34045393-162A1B14-72C4-4496-A99A-40F8F0F62EF6 Q34202863-D33A20DA-DFDF-4E82-AFC4-71D57AC870E1 Q34356540-852E37E7-65E3-4AC6-865E-3B56A30EA5C3 Q34413659-CAA5DDBA-6873-4C21-8D5C-3442CEA7173C Q34627494-15100AE2-BFF4-4C56-B91D-888A3C630427 Q34628607-EE282DE1-7E61-4786-9AA1-96A7AA803B84 Q34634538-5C498C71-135A-494F-AB3E-C601D8AC3A31 Q34635550-477C9B7F-B34B-42AC-B7F4-829F19682B7B Q34652142-8E64977F-EEFE-44E4-B668-C2D1DA41F84B Q34659806-01006F06-B8FF-41DF-BD37-E7E52E36B5AD Q34664479-3B3E1B43-C9BE-44C0-A8E7-88BBF24015B6 Q34674564-CAD2D510-1D48-4E5F-96FE-53293274E531 Q34736667-09489DD4-4A93-4CAF-A3AF-BC95B06466AF Q34952133-9D983971-F7C7-48D2-8726-E9F11BF9DF5B Q35013284-DE651C74-B584-470A-B1CD-D256C9ED142C Q35044274-8EC80729-EB33-47C7-89AD-8A03863B2118 Q35058617-95085220-68F2-44F7-BAB0-A327C6E34EED Q35060225-D0F82C71-C4F4-4512-B0F5-8D4109BBD66F Q35103320-BEC8E99B-E49A-4A2B-9A83-4A91D565491D

P2860

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

http://www.wikidata.org/entity/Q36856816

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Efficacy of trabectedin (ectei ...... rcomas: a retrospective study.

@en

type

label

Efficacy of trabectedin (ectei ...... rcomas: a retrospective study.

@en

prefLabel

Efficacy of trabectedin (ectei ...... rcomas: a retrospective study.

@en

P1433

Q36856816-B51E0F90-E219-47FE-9EAB-F00F09A831CC

P1476

Q36856816-7F6FEB0F-D304-4B5E-A05E-1928BAFD2058

P2093

Q36856816-35521784-4AA7-437A-A518-85159F200493

Q36856816-3AFBAB57-3B42-4946-B503-4854B431C0D8

Q36856816-3E5F306E-41DC-4E07-B05F-982DC08C37AC

Q36856816-3FAF6A97-EF4F-4A57-AA76-DF22F49C6112

Q36856816-49052159-D791-47AD-8D44-689BE2A2BF26

Q36856816-60E297A4-4A83-4B67-99B5-4530DB463A19

Q36856816-8F411165-761B-42BF-9BF8-3C6D9F9DCB18

Q36856816-AD35D4E5-2037-429A-BC0B-275532B6AA58

Q36856816-CF8CDEDA-7D4F-4335-B2BE-EC5A26014CAD

Q36856816-FF8FB32B-ADEF-474E-BA98-AD2DD621D2FA

P304

Q36856816-630EDFA0-5EE5-45E2-B700-F447058EAA83

P31

Q36856816-AF684F5C-7B0E-4895-B8DF-C2A30995EAF3

P356

Q36856816-78DAF35B-A311-4A68-BBC4-3844D7369A34

P433

Q36856816-ECE55B3F-23A7-484D-8391-B3B04D77E0AB

P478

Q36856816-228FCFB3-C4E2-4A2D-B1C3-371A3DCD37AC

P50

Q36856816-074B6760-626F-4C50-B7C8-46536970A900

Q36856816-1771AA66-5BE1-41E6-99EF-8832B2914653

Q36856816-19CD59EC-7F61-434A-AF5D-2C0178808933

Q36856816-2E421AB7-A1A0-4447-B618-3E6CEADC6976

Q36856816-31781A0F-1495-4E22-AEB0-59164BFE9AFF

Q36856816-523DC1D5-59C2-492B-A8C1-11F45D9D82C4

Q36856816-63470B84-1819-41E1-B14B-495925A44E04

Q36856816-6F8E4611-F934-4A0A-9890-BD300FAC9DB1

Q36856816-9A0747F5-092C-401A-8BBC-C42B4B4B2312

Q36856816-E1F7D659-C71B-48CE-B6C3-44D56716602F

P577

Q36856816-DBD2EA6C-5CD1-4128-9E2B-824EB7A0A7B3

P698

Q36856816-B2A0DCE6-A0EC-4A32-991D-5238634DF65E

P356

S1470-2045(07)70175-4

P1433

The Lancet Oncology

P1476

Efficacy of trabectedin (ectei ...... rcomas: a retrospective study.

@en

P2093

Federica Grosso

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Ian R Judson

http://www.w3.org/2001/XMLSchema#string

Jonathan A Fletcher

http://www.w3.org/2001/XMLSchema#string

Josè Jimeno

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Tercero

http://www.w3.org/2001/XMLSchema#string

Palma Dileo

http://www.w3.org/2001/XMLSchema#string

Paola Casieri

http://www.w3.org/2001/XMLSchema#string

Robin L Jones

http://www.w3.org/2001/XMLSchema#string

Silvana Pilotti

http://www.w3.org/2001/XMLSchema#string

P304

595-602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(07)70175-4

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Gronchi

Paolo Giovanni Casali

Elena Tamborini

Carlo Spreafico

Maurizio D'Incalci

Roberta Sanfilippo

Silvia Stacchiotti

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17586092

http://www.w3.org/2001/XMLSchema#string